Kite Pharma (KITE) Post Smaller Q2 Loss on Higher Revs

Kite Pharma (NASDAQ: KITE) reported Q2 EPS of ($1.50), $0.48 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $9.59 million.

"We've continued to make significant progress on key clinical and commercial milestones in the last six months alone," said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. "With the anticipated events on the horizon for the remainder of 2017, the potential for CAR-T to become one of the most powerful anti-cancer agents for certain patients may finally be realized."

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Deutsche Bank Upgrades SMA Solar Technology AG (S92:GR) to Buy
• UnitedHealth Group (UNH) Tops Q2 EPS by $1.53, Beats on Revenue; Offers FY26 EPS Guidance